Stiolto Respimat is a Respiratory (inhalation) Spray, Metered in the Human Prescription Drug category. It is labeled and distributed by Boehringer Ingelheim Pharmaceuticals Inc.. The primary component is Tiotropium Bromide Monohydrate; Olodaterol Hydrochloride.
Product ID | 0597-0155_0ae2698c-8f15-8481-9173-45caaaa3ef5c |
NDC | 0597-0155 |
Product Type | Human Prescription Drug |
Proprietary Name | Stiolto Respimat |
Generic Name | Tiotropium Bromide And Olodaterol |
Dosage Form | Spray, Metered |
Route of Administration | RESPIRATORY (INHALATION) |
Marketing Start Date | 2015-05-21 |
Marketing Category | NDA / NDA |
Application Number | NDA206756 |
Labeler Name | Boehringer Ingelheim Pharmaceuticals Inc. |
Substance Name | TIOTROPIUM BROMIDE MONOHYDRATE; OLODATEROL HYDROCHLORIDE |
Active Ingredient Strength | 3 ug/1; ug/1 |
Pharm Classes | Anticholinergic [EPC],Cholinergic Antagonists [MoA],beta2-Adrenergic Agonist [EPC],Adrenergic beta2-Agonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2015-05-21 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA206756 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | GM |
Marketing Start Date | 2018-07-02 |
Marketing Category | NDA |
Application Number | NDA206756 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | GM |
Marketing Start Date | 2015-05-21 |
Marketing Category | NDA |
Application Number | NDA206756 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2015-05-21 |
Marketing Category | NDA |
Application Number | NDA206756 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | GM |
Marketing Start Date | 2019-03-22 |
Ingredient | Strength |
---|---|
TIOTROPIUM BROMIDE MONOHYDRATE | 3.124 ug/1 |
SPL SET ID: | 01e15aee-40e0-23f3-537f-c96dd63e2cb1 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
STIOLTO RESPIMAT 88237756 not registered Live/Pending |
Boehringer Ingelheim International GmbH 2018-12-20 |